Wedbush Reiterates Rating on Immunome, Inc. $IMNM
Key Points
- Wedbush now rates Immunome, Inc. ($IMNM) "buy" with a $31.00 target.
- The Street's average $IMNM price target is $35.77 (Strong Buy).
- $IMNM last traded around $18.38.
Wedbush reiterated its rating on Immunome, Inc. ($IMNM) to a "buy" rating, with a price target of $31.00 in a recent research note.
Immunome, Inc. ($IMNM) Stock
Immunome, Inc. Earnings
Analysts Set New Price Targets
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.